duloxetine hydrochloride has been researched along with methylphenidate in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Naguy, A | 1 |
Collin-Lévesque, L; El-Ghaddaf, Y; Ferreira, E; Genest, M; Jutras, M; Leclair, G; Panchaud, A; Weisskopf, E | 1 |
Manu, P | 1 |
3 other study(ies) available for duloxetine hydrochloride and methylphenidate
Article | Year |
---|---|
Duloxetine Alleviates Stimulant Dysphoria, Helps With Enuresis, and Complements Cognitive Response in an Adolescent With Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cognition; Drug Therapy, Combination; Duloxetine Hydrochloride; Enuresis; Humans; Male; Methylphenidate; Serotonin and Noradrenaline Reuptake Inhibitors | 2016 |
Infant Exposure to Methylphenidate and Duloxetine During Lactation.
Topics: Adult; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Breast Feeding; Depressive Disorder; Dietary Exposure; Duloxetine Hydrochloride; Female; Humans; Infant, Newborn; Lactation; Methylphenidate; Milk, Human; Mothers; Pregnancy; Risk Assessment; Selective Serotonin Reuptake Inhibitors | 2018 |
Repurposing Drugs for Post-COVID-19 Fatigue Syndrome: Methylphenidate, Duloxetine, and Brexpiprazole.
Topics: COVID-19; Drug Repositioning; Duloxetine Hydrochloride; Fatigue; Humans; Methylphenidate; Quinolones; Thiophenes | 2022 |